08/20/20
After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.'s MHRA Accepts CytoDyn's Request to Enroll in its Current Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms
Press Release
08/20/20
To Avoid Delay, the FDA Recommends CytoDyn Conduct Its Type A Meeting in Writing with FDA Response Goal Date of September 4
Press Release
08/19/20
CytoDyn Announces Upcoming Retirement of Dr. David Welch from its Board of Directors
Press Release
08/19/20
CytoDyn Requests "Fast Track Approval" for COVID-19 Patients from U.K.'s Regulatory Agency MHRA based on its Top-line Report Showing Statistically Significant Endpoint, NEWS2 (p < 0.023) and Notable Safety Results
Press Release
08/17/20
CytoDyn Will Attempt to Duplicate Berlin and London Patients' HIV Cure by Using Leronlimab During Bone Marrow Transplant for 5 HIV Patients Who also have Cancer
Press Release
08/17/20
CytoDyn Submits its Top-line Report from its Phase 2 COVID-19 Trial to the U.S. FDA and Requests Emergency Use Approval
Press Release
load more
?
Key Stock Data
P/E Ratio (TTM)
N/A
EPS (TTM)
$-0.28
Market Cap
$1.72 B
Shares Outstanding
568.24 M
Public Float
491.20 M
Yield
CYDY is not currently paying a regular dividend.
Latest Dividend
N/A
Ex-Dividend Date
N/A
?
Short Interest ()
N/A
?
Stock Money Flow
N/A
Research & Ratings CytoDyn Inc.
Per-Share Earnings, Actuals and Estimates
Quarterly
Annual
CYDY will report Q1 earnings on 10/28/2020
Actual Analyst Range Consensus
0.05 0.00 -0.05 -0.10
Q12019 Q2 Q3 Q4 Q12020 Q2
Q1 2020 Estimate Trends
Current: $-0.06
1 month ago: $0.05
3 months ago: $0.05
Q2 2020 Estimate Trends
Current: $-0.05
1 month ago: $0.09
3 months ago: $0.09
More
Financials CytoDyn Inc.
Quarterly
Annual
Net Income
0
0 -90M
Feb 2019 May 2019 Aug 2019 Nov 2019 Feb 2020
Feb 2020 5-quarter trend
Net Income Growth -184.46%
Sales or Revenue -
Sales or Revenue Growth -
EBITDA -21.57 M
More
Advertisement
Competitors CYDY
Company Change P/E (TTM)
United Therapeutics Corp.
+0.52% 11.03
Chimerix Inc.
-4.71% -
More information on CYDY Competitor Data Provided By: capital cube
Profile CYDY
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company...
1111 Main Street
Vancouver Washington 98660
United States
got this off wsj
